Related Experiment Video

Updated: Aug 12, 2025

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.3K

Molecular bottlebrush prodrugs as mono- and triplex combination therapies for multiple myeloma

Alexandre Detappe1,2,3, Hung V-T Nguyen1,2,4,5, Yivan Jiang4,5

  • 1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.

Nature Nanotechnology
|January 26, 2023
PubMed

Insights

New bottlebrush prodrugs (BPDs) improve multiple myeloma treatment. These nanomedicines effectively deliver multiple drugs, outperforming traditional combinations and single-drug nanocarriers for better cancer therapy outcomes.

Area of Science:

  • Nanomedicine
  • Drug Delivery Systems
  • Oncology

Background:

  • Cancer therapies face challenges with narrow therapeutic indexes and suboptimal drug combinations due to differing physical properties.
  • Nanomedicine platforms offer potential solutions, but their efficacy in delivering synergistic drug ratios and outperforming single-drug carriers requires investigation.

Purpose of the Study:

  • To develop and evaluate a bottlebrush prodrug (BPD) platform for multiple myeloma therapy.
  • To determine if synergistic free-drug ratios translate to nanocarriers and compare multi-drug BPDs against single-drug BPD mixtures.

Main Methods:

  • Development of a bottlebrush prodrug (BPD) platform for cancer therapy.
  • In vivo evaluation of bortezomib-based BPD monotherapy in multiple myeloma models.
  • In vitro assessment of drug combinations (bortezomib, pomalidomide, dexamethasone) within BPDs and comparison with free-drug counterparts and single-drug BPD mixtures.

Main Results:

  • BPD monotherapy demonstrated efficacy in slowing tumor progression in vivo.
  • Mixtures of BPDs with multiple drugs showed distinct in vitro synergistic, additive, or antagonistic patterns compared to free drugs.
  • Multi-drug BPDs in a synergistic ratio outperformed both free-drug combinations and mixtures of single-drug BPDs at the same ratio.

Conclusions:

  • Bottlebrush prodrugs provide a viable platform for developing advanced combination nanomedicines.
  • The study offers design principles for nanomedicines, potentially improving current therapies for multiple myeloma.
  • This research addresses key questions regarding drug synergy and nanocarrier performance in combination cancer therapy.

More Related Videos

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice05:32

Multimodal Bioluminescent and Positronic-emission Tomography/Computational Tomography Imaging of Multiple Myeloma Bone Marrow Xenografts in NOG Mice

Published on: January 7, 2019

6.9K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

8.7K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Combined Effects of Drugs: Synergism01:27

Combined Effects of Drugs: Synergism

Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
4.4K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
2.0K